Morbidities and Mortality in Transfusion-Dependent Beta-Thalassemia Patients (Single-Center Experience)

REFERENCES

• El-Beshlawy A, Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin. 2009;33(1):S14–S20.
   Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40–47.
   PubMed Web of Science ®Google Scholar
• Hershko C, Cappellini MD, Galanello R, Purging iron from the heart. Br J Haematol. 2004;125:545–551.
   PubMedGoogle Scholar
• Rund D, Rachmilewitz E. New trends in the treatment of β-thalassemia. Crit Rev Oncol Hematol. 2000;33:105–118.
   PubMed Web of Science ®Google Scholar
• Oliveri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Melelis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792–800.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematol/Hematol J. 2007;92(05):658–665.
   PubMedGoogle Scholar
• Adam Kwicz TV, Benk ovitch M, Krishnan C, Beta-thalassemia incidence and predisposing factors. Clin Infect Dis. 1998;27(6):1362–1366.
   Google Scholar
• Cohen A, Eletheriou A, Piga A, Porter J. Prevelance of endocrine complication in thalassemia major, Italy. Clin Endocrinol. 2000:42–581.
   Google Scholar
• Rati D, Cappellini C, Zanella A, Asymptomatic hepatitis G virus infection in blood donors. Transfusion. 1997;37:1200–1204.
   PubMedGoogle Scholar
• Perifanis V, Tziomalos K, Tsatra I, Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. Haematologica. 2005;90(8):1136–1138.
   PubMedGoogle Scholar
• Voskaridou E, Terpos E, Michail S, Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int. 2006;69(11):1927–1930.
   PubMedGoogle Scholar
• Haynes RB, Taylor W, Sackett DL, Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2:757–764.
   PubMed Web of Science ®Google Scholar
• Ashena Z, Ghafurian S, Ehsani MA. The relation between the left ventricular diastolic indices and serum ferritin in thalassemia major. Pediatr Hematol Oncol. 2007;24:3–14.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, A comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530.
   PubMed Web of Science ®Google Scholar
• Gordon CM, Bachrach LK, Carpenter TO, Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD pediatric official positions. J Clin Densitom. 2008;11(1):43–58.
   PubMed Web of Science ®Google Scholar
• Lanzkowsky P. Non Hodgkin disease. Manual Of Pediatric Hematology and Oncology. 3rd ed. California: Academic Press; 2000:445–469.
   Google Scholar
• Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from deferoxamine to deferiprone in beta-thalassemia major patients. Hemoglobin. 2006;30(2):229–238.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–3744.
   PubMed Web of Science ®Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Complications of beta-thalassemia major in North America. Blood. 2008;104(1):34–39.
   Google Scholar
• Aessopos A, Farmakis D, Deftereos S, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530.
   PubMed Web of Science ®Google Scholar
• Bosi G, Crepaz R, Gamberini MR, Left ventricular remodeling, and systolic and diastolic function in young adults with β-thalassemia major: a Doppler echocardiographic assessment and correlation with hematological data. Heart. 2003;89:762–766.
   PubMed Web of Science ®Google Scholar
• Zakynthinos E, Vassilakopoulos T, Kaltsas P, Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001;56:737–739.
   PubMedGoogle Scholar
• Derchi G, Forni GL, Formisano F, Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobino-pathies. Haematologica. 2005;90:452–458.
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Styles L, Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am. J. Hematol. 2006;81:670–675.
   PubMed Web of Science ®Google Scholar
• Mohkam M, Shamsian BS, Gharib A, Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol. 2008;23(6):971–976.
   PubMed Web of Science ®Google Scholar
• Aldudak B, Karabay Bayazit A, Noyan A, Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000;15(1–2):109–112.
   PubMed Web of Science ®Google Scholar
• Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and hemodialysis patients in north Tran-Rasht. J Viral Hepat. 2002;9(5):390–392.
   PubMedGoogle Scholar
• Batubara JRL, Akib A, Pramita D. Delayed puberty in thalassemia major patients. Indones. 2004;44:143–147.
   Google Scholar
• Shamshirsaz AA, Bekheirnia MR, Kamgar M, Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord. 2003;3:3–4.
   PubMedGoogle Scholar
• Telfer PT, Warburton F, Christou S, Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777–1778.
   PubMed Web of Science ®Google Scholar
• Montazare LE, Hashemi A, Behjati SM, The relation between left ventricular function and serum ferritin in major β-thalassemia. Iranian J Pediatr Hematol Oncol. 2011;1(3):94–97.
   Google Scholar
• Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med. 2006;9(4):329–334.
   PubMedGoogle Scholar
• Vaccari M, Crepaz R, Fortini M, Left ventricular remodeling, systolic function, and diastolic function in young adults with beta-thalassemia intermedia: a Doppler echocardiography study. Chest. 2002;121:506–512.
   PubMed Web of Science ®Google Scholar
• Abdelrazik N, Ghanem H. Failure of puberty in Egyptian beta-thalassemic patients: experience in north east region—Dakahlia province. Hematology. 2007;12(5):449–456.
   PubMed Web of Science ®Google Scholar
• Baldini M, Forti S, Marcon A, Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol. 2010;89(12):1207–1213.
   PubMed Web of Science ®Google Scholar
• Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta-thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315–319.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876– 1884.
   PubMed Web of Science ®Google Scholar
• Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann NY Acad Sci. 2005;1054:175– 182
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Galanello R, Piras S, Barella S, Cholelithiasis and Gilbert's syndrome in homozygous β-thalassaemia. Br J Haematol. 2001;115(4):926–928.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42,(3),247–251.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489–496.
   PubMed Web of Science ®Google Scholar
• Bazrgar M, Peiravian F, Abedpour F, Karimi M. Causes for hospitalization and death in Iranian patients with β-thalassemia major. Pediatr Hematol Oncol. 2011;28(2):134–139. Epub.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M, Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;25;10:42.
   Google Scholar